Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT00640523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: forodesine HCl

Sponsor

BioCryst Pharmaceuticals